Logo

Fermion’s FZ008-145 Receives IND Approval by China’s NMPA for Pain Relief

Share this
Fermion

Fermion’s FZ008-145 Receives IND Approval by China’s NMPA for Pain Relief

Shots:

  • The company’s IND application for FZ008-145 has been approved by China’s NMPA for 5 acute pain and 1 chronic pain proof-of-concept (POC) trials
  • Joincare Pharmaceutical holds exclusive rights to the company's FZ008-145 in the Greater China region while Fermion has the rights outside of Greater China
  • FZ008-145 is a non-addictive pain relief drug that targets Nav1.8 aimed at providing powerful, non-addictive pain relief advantages

Ref: PRNewswire | Image: Fermion

Related News:- Abbott to Launch NeuroSphere myPath App to Record Pain Relief in Chronic Pain Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions